Arm 1: Methylcobalamin → methionine synthase → SAMe → myelin
The first enzymatic arm of B12 operates in the cytoplasm. Methylcobalamin serves as the cofactor for methionine synthase (MTR), converting homocysteine to methionine. Methionine is then adenylated to form S-adenosylmethionine (SAMe) — the body's universal methyl donor.
For nerves, SAMe's critical role is phosphatidylcholine synthesis — the primary phospholipid in myelin sheaths. Schwann cells use SAMe-derived methyl groups to build the myelin that wraps and insulates peripheral nerve axons.
The chain: B12 deficiency → methionine synthase stalls → homocysteine accumulates → SAMe production drops → Schwann cells cannot synthesise sufficient myelin phospholipids → progressive demyelination → nerve conduction slows → tingling, numbness, loss of vibration sense.
This is why B12 deficiency produces neurological symptoms even before anaemia develops — the nervous system's myelin demand is continuous and sensitive to methylation disruption.
Arm 2: Adenosylcobalamin → methylmalonyl-CoA mutase → mitochondrial energy
The second enzymatic arm operates inside mitochondria — and this is the arm most articles about "B12 for nerves" fail to explain.
Adenosylcobalamin (AdoCbl) is the cofactor for methylmalonyl-CoA mutase (MCM), a mitochondrial enzyme that converts methylmalonyl-CoA to succinyl-CoA. Succinyl-CoA enters the TCA cycle, feeding oxidative phosphorylation — the primary ATP source for cells.
Why this matters specifically for nerves
Motor and sensory neurons have the longest axons in the body (up to 1 metre in lower limbs). These axons depend on continuous mitochondrial ATP production to maintain:
- Na⁺/K⁺-ATPase pump activity — essential for repolarisation after each action potential
- Axonal transport — kinesin and dynein motor proteins require ATP to shuttle organelles, vesicles, and trophic factors along microtubules
- Synaptic vesicle recycling — neurotransmitter release and reuptake at nerve terminals is ATP-dependent
When adenosylcobalamin is deficient, MCM cannot function. Methylmalonic acid (MMA) accumulates — this is both a diagnostic marker (elevated MMA confirms tissue-level B12 deficiency) and a direct pathological agent:
MMA displaces normal fatty acids in myelin
Accumulated MMA and its precursor methylmalonyl-CoA are incorporated into fatty acid synthesis in place of normal substrates. This produces abnormal odd-chain and branched-chain fatty acids that are incorporated into myelin phospholipids — creating structurally defective myelin sheaths that are less stable and degrade faster than they can be repaired.
ATP deficit in distal axons
With the TCA cycle running below capacity, mitochondrial ATP output drops. The longest axons — those serving the feet and hands — are affected first because they have the highest energy transport costs. This explains the characteristic stocking-glove distribution of B12 neuropathy: symptoms start distally and progress proximally.
Clinical significance: Elevated MMA (>0.4 μmol/L) confirms that the adenosylcobalamin arm is impaired — even when serum B12 appears borderline (200–400 pg/mL). This makes MMA the most specific functional marker of B12 deficiency at the tissue level.
Schwann cell biology: why myelin loss is not instant and recovery is not fast
Schwann cells are the sole myelin-producing cells in the peripheral nervous system. Understanding their biology explains both the timeline of B12 neuropathy and the timeline of recovery:
One Schwann cell, one internode
Unlike oligodendrocytes in the CNS (which myelinate multiple axon segments), each Schwann cell wraps a single internodal segment of one axon. The gaps between Schwann cells are the nodes of Ranvier — where voltage-gated sodium channels cluster to enable saltatory conduction (the jumping of action potentials from node to node).
Continuous myelin turnover
Myelin is not a static structure. Schwann cells continuously turn over myelin lipids — synthesising new phosphatidylcholine, phosphatidylethanolamine, and sphingomyelin via SAMe-dependent methyltransferase reactions. When B12 is adequate, synthesis keeps pace with degradation. When B12 is deficient, synthesis slows while degradation continues — producing net myelin loss.
Why demyelination is gradual, not sudden
Because myelin turnover is continuous rather than event-based, B12 deficiency does not cause acute demyelination. Instead, it produces a slow erosion — myelin lamellae thin over weeks to months, increasing internodal capacitance and decreasing conduction velocity progressively. This is why early B12 neuropathy presents as subtle tingling or reduced vibration sense rather than sudden paralysis.
Recovery timeline: remyelination vs. metabolic recovery
| Fibre type | Mechanism of damage | Recovery process | Timeline |
|---|---|---|---|
| Large myelinated (Aα, Aβ) | Demyelination (SAMe pathway failure) | Schwann cell remyelination — new myelin lamellae synthesis | 8–12 weeks minimum |
| Small unmyelinated (C fibres) | Axonal energy failure (AdoCbl/mutase pathway) | Mitochondrial metabolic recovery — ATP restoration | 4–8 weeks |
This explains why some patients with B12 deficiency recover sensation (small-fibre) faster than coordination (large-fibre) — and why early intervention matters: once axonal loss replaces demyelination, recovery is limited.
Diagnostic thresholds: when to suspect B12-related neuropathy
Serum B12 testing alone is insufficient for evaluating neurological risk. A complete assessment requires functional markers:
| Marker | Threshold | Which B12 arm it reflects |
|---|---|---|
| Serum B12 | <200 pg/mL | Both arms — frank deficiency |
| Serum B12 | 200–400 pg/mL | "Grey zone" — functional deficiency possible, needs MMA |
| MMA | >0.4 μmol/L | Adenosylcobalamin arm — mutase pathway impaired |
| Homocysteine | >15 μmol/L | Methylcobalamin arm — methionine synthase impaired (also folate) |
Critically, neurological symptoms can develop before haematological changes. A patient can have normal haemoglobin and MCV but still have B12-related demyelination — serum B12 with MMA confirmation is the minimum diagnostic panel (Langan & Goodbred 2017).
B12 is necessary but not sufficient: the multi-vitamin nerve framework
B12 handles two arms of nerve health (methylation/myelin + mitochondrial energy), but peripheral nerves also require:
- Benfotiamine (fat-soluble B1) — activates transketolase in the pentose phosphate pathway, providing axonal energy substrates. Also inhibits AGE formation in diabetic neuropathy (BEDIP trial, Winkler 2005)
- P-5-P (active B6) — cofactor for AADC and GAD, required for GABA, serotonin, and dopamine synthesis
- 5-MTHF (active folate) — provides the methyl group that B12-dependent methionine synthase transfers to homocysteine. Without folate, B12 alone cannot drive the SAMe pathway
This is why comprehensive nerve formulas — like Cobascore — include multiple active B vitamins rather than B12 alone. Each handles a distinct biochemical arm of nerve maintenance.